Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder
Sponsor: Asad Ullah Jan
Summary
The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.
Official title: Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-05-06
Completion Date
2025-12-31
Last Updated
2025-07-09
Healthy Volunteers
No
Conditions
Interventions
Dextromethorphan-Bupropion
Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.
SSRIs
Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.
Locations (2)
Combined Military Hospital
Nowshera, KPK, Pakistan
Department of Psychiatry, Combined Military Hospital Nowshera
Nowshera, KPK, Pakistan